Skip to main content

Table 1 Baseline characteristics of patients in five PTH response groups

From: Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study

 

PTH change group

 

Patient characteristics

No PTH reduction

Quartile 1

Quartile 2

Quartile 3

Quartile 4

P

n

982

621

621

621

622

 

Mean (SD) percent change in PTH

+38.5 (43.9)

−11.2 (6.1)

−31.8 (5.8)

−52.2 (6.1)

−78.2 (9.2)

NA

Age, yrs.

Mean (SD)

57.8 (15.0)

57.7 (14.7)

59.2 (14.4)

61.0 (14.1)

62.6 (13.4)

<0.0001

18-44

20.7

21.1

17.4

13.7

10.0

<0.0001

45-64

44.7

43.6

45.3

43.8

43.1

 

65-74

20.7

22.1

23.8

25.3

28.1

 

≥75

14.0

13.2

13.5

17.2

18.8

 

Race

      

African American

53.1

51.9

49.6

50.6

48.9

0.48

White

24.8

26.9

28.2

27.5

25.4

 

Other

22.2

21.3

22.2

21.9

25.7

 

Male sex

53.8

54.9

54.9

49.6

46.5

0.01

Dialysis duration, yrs., mean (SD)

6.0 (4.6)

5.8 (4.4)

5.8 (4.1)

5.4 (4.0)

5.8 (4.4)

0.3

BMI, kg/m2, mean (SD)

27.5 (7.2)

27.7 (6.9)

27.9 (7.0)

27.9 (7.2)

27.1 (6.3)

0.23

Intact PTH, pg/mL, pre-cinacalcet prescription

Mean (SD)

687 (387)

798 (500)

756 (454)

739 (379)

740 (386)

 

>300- ≤ 600

54.9

42.8

46.7

45.7

44.7

<0.0001

>600

45.1

57.2

53.3

54.3

55.3

 

Corrected calcium, mg/dL

Mean (SD)

9.83 (0.7)

9.70 (0.7)

9.70 (0.7)

9.72 (0.7)

9.64 (0.7)

 

<9.0 mg/dL

11.0

14.7

11.1

10.6

13.7

<0.0001

≥9.0- ≤ 10.2

60.2

62.3

68.4

69.2

70.6

 

>10.2

28.8

23.0

20.5

20.1

15.8

 

Phosphorus, mg/dL

Mean (SD)

6.4 (1.8)

6.4 (1.6)

6.1 (1.5)

5.9 (1.5)

5.9 (1.5)

<0.0001

<3.5 mg/dL

2.6

1.5

2.3

3.4

1.9

0.0002

≥3.5– ≤ 5.0

19.7

19.5

22.5

25.1

28.8

 

>5.0

77.8

79.1

75.2

71.5

69.3

 

Kt/V, mean (SD)

1.7 (0.4)

1.7 (0.4)

1.7 (0.5)

1.7 (0.4)

1.7 (0.4)

0.85

Primary cause of ESRD

      

Diabetes

36.1

38.2

41.2

38.0

45.2

0.07

Hypertension

34.6

33.2

31.1

34.6

31.2

 

Glomerulonephritis

13.2

11.9

13.5

11.0

10.6

 

Other

16.1

16.8

14.2

16.4

13.0

 

Hospital days

0

60.6

65.4

64.3

60.4

59.8

0.53

1-2

8.4

7.3

7.1

9.5

7.1

 

3-5

10.5

9.5

9.2

10.3

11.7

 

>5

20.6

17.9

19.5

19.8

21.4

 

Phosphate binder use at first cinacalcet prescription

Calcium containing

41.0

40.6

39.6

40.4

44.1

0.56

Non-calcium containing

81.3

80.4

80.8

79.6

77.0

0.30

Combination

26.8

24.8

24.0

24.8

24.4

0.72

None

4.5

3.9

3.5

4.8

3.4

0.62

Comorbidity

ASHD

26.0

24.2

27.5

32.4

28.8

0.01

CHF

26.3

25.0

25.4

28.2

28.6

0.49

CVA/TIA

9.2

8.9

8.4

9.7

9.5

0.94

PVD

24.5

23.2

24.6

27.9

28.9

0.09

Other cardiac disease

23.0

24.6

24.0

21.9

22.0

0.73

COPD

11.4

11.6

11.1

11.9

12.7

0.92

GI disease

5.5

4.2

5.2

6.6

6.6

0.29

Liver disease

2.4

1.8

1.3

2.7

2.4

0.38

Dysrhythmia

16.5

17.4

18.5

19.7

18.8

0.53

Cancer

3.6

5.6

4.8

6.3

4.3

0.11

Diabetes

47.9

50.9

53.0

53.1

55.7

0.03

Days from last PTH level to first cinacalcet prescription

15.4 (13.5)

14.2 (12.1)

13.1 (10.9)

14.3 (12.2)

14.7 (12.6)

0.01

  1. Patients were grouped based on quartiles of PTH decrease from first cinacalcet prescription. Patients whose PTH levels increased or remained unchanged were assigned to “no PTH reduction” group.
  2. Results are reported as percentage of patients or mean ± standard deviation. P values: We used analysis of variance (ANOVA) and chi-square tests to evaluate differences in continuous and categorical characteristics, respectively, across all PTH change groups.
  3. ASHD, atherosclerotic heart disease; BMI, body mass index determined using height and weight; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebral vascular accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal; PTH, parathyroid hormone; PVD, peripheral vascular disease; SD, standard deviation.